Figure 3.

Overall(OS) and relapse-free survival (RFS) in patients with ctDNA+ versus ctDNA− at the first collection post-surgery (landmark). We observed a significant prolongation of median OS in patients with ctDNA− in this population (A). No significant difference was observed in terms of RFS for the overall population based on post-op ctDNA detectability when considering both local and systemic recurrence (B). However, patients with a positive landmark collection had a significantly shorter systemic RFS (C). ctDNA, circulating tumor DNA; HR, hazard ratio; KM, Kaplan-Meier curves.